{"name":"Enzon Pharmaceuticals","slug":"enzon","ticker":"ENZN","exchange":"OTC","domain":"enzon.com","description":"Enzon Pharmaceuticals, Inc. is a pharmaceutical company. Its headquarters is in Piscataway, New Jersey. The company is a publicly traded company on NASDAQ under the symbol \"ENZN\". It's also doing marketing works in Asia areas such as China. In 2012, the company orally presented in Nanjing, China about the symposium of its drug delivery systems, which help improve therapeutic molecules' pharmaceutical properties.","hq":"Bridgewater, NJ","founded":0,"employees":"","ceo":"Andrew Rackear","sector":"Legacy Biotech / Royalties","stockPrice":5.75,"stockChange":-0.5,"stockChangePercent":-8,"marketCap":"$38M","metrics":{"revenue":356704992,"revenueGrowth":-8.1,"grossMargin":8.8,"rdSpend":0,"netIncome":-3409000,"cash":28619000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2033-06-01","label":"Alkindi patent cliff ($13.4M at risk)","drug":"Alkindi","type":"patent_expiry","sentiment":"negative"},{"date":"2034-06-01","label":"Zinforo patent cliff ($0.1M at risk)","drug":"Zinforo","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Enzon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Enzon Pharmaceuticals reported its fourth quarter and full year 2023 financial results, with revenue of $13.4 million and a net loss of $2.5 million.","drugName":"","sentiment":"neutral"},{"date":"2023-12-01","type":"deal","headline":"Enzon Pharmaceuticals Announces License Agreement with Merck KGaA","summary":"Enzon Pharmaceuticals announced a license agreement with Merck KGaA for the development and commercialization of Alkindi in the United States.","drugName":"","sentiment":"positive"},{"date":"2023-09-01","type":"regulatory","headline":"Alkindi Receives FDA Approval for the Treatment of Adrenal Insufficiency in Infants and Young Children","summary":"Alkindi, a proprietary formulation of hydrocortisone, received FDA approval for the treatment of adrenal insufficiency in infants and young children.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQTGROZTYtZjZCUVhNaUJJb1lfazJmRzkyZm9wcTgyX1RRNXJZZllXeXV4ZUwxR3dRMTV1NlIxR2NaZHBuQUVreHFyYWhKeVhSWHBSd21mbF9QZWlwTzNUVTRBbkZRZjJDMmVrWG9FcHZwUHF1SWNZZ21qcGZTWFVPYU9Gc0h5OFhIY1h0Mk53OFd2QnNPZDBrdE1tVXJfMVppdVk4VGxseFdXUkoxWDhVUG51cnlvbDdhRFJj?oc=5","date":"2026-03-27","type":"deal","source":"Stock Titan","summary":"Icahn-affiliated entities reshape Viskase Holdings (ENZN) stake in merger - Stock Titan","headline":"Icahn-affiliated entities reshape Viskase Holdings (ENZN) stake in merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxOaFBLUGdmeFZ1UDRaU3BSaGFLMW45clo0SEdwbkpnMFhJaUR4T0RZWXp3eFNjVDRSczRHS2NvMVNVTElGSlVYdGVSUWtaZnQxNjVVWUktbVRnaVRuUm1xNlNjWlEwS3JXUW9zZTBtQkFzMkx1RWtSWGJLZHNUSDNCTHpmM0Z4ZS15OGFUVjA1Z2x6LXIzYVp2ZFNfRThINDJWUkxTX05aRThjc0M4Q2lmRFNJeFNuT3R4Wmp2eGRKUUxGa2RhWHlpbEM5Yw?oc=5","date":"2026-03-27","type":"deal","source":"Stock Titan","summary":"Icahn entities lift Viskase (ENZN) stake to 93.7% after merger - Stock Titan","headline":"Icahn entities lift Viskase (ENZN) stake to 93.7% after merger","sentiment":"neutral"},{"date":"2026-03-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPcXF0TTN2RUl2eTI2TjhFb3RkdWhzUXVDeEQwdEcyRUlrek5ZMFRGcmdUYjBWWFI5LUtIV1JJTHNxT0RLa08wZktUVk4wR2J1MU14NkpLdTNMMEctUGVlUllUTVNPSUZ5bXFEdXpNWHhERTF4c2tWYmZGMjltYkpDbFdJOWFnTTl3cjNBLXhQY0R5WlFGeTluSXY2bGtqQzRncUY5TzFWR2pnekRmUk4yc0JRTFQ?oc=5","date":"2026-03-24","type":"deal","source":"Stock Titan","summary":"Enzon Pharmaceuticals (ENZN) enacts 1-for-100 reverse split tied to Viskase merger - Stock Titan","headline":"Enzon Pharmaceuticals (ENZN) enacts 1-for-100 reverse split tied to Viskase merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPeDd1aGZXVXZwcHg4UVE5dHlSQlFVb2lrLTBaOXNOamphWlBOZndqRks2MG5jN1RXZ2MxWTVWS0FUc0w4VVpfZVh2bFZWVWxjTV93dzV4bnhvQVBzbG41azIzaHFIbE53Tk1RTGR5VUVxdXdyaHlBNXBfTE9rZnhOVU5MWWlvNDl4ZEtnWjZYZUEwWWJSdHhNU3RRa09XNDI2TFlDSjV5bUc1d0lmTmlVYV9hMnNhbm5uSnh0dFpoeUVEZHpw?oc=5","date":"2026-03-24","type":"pipeline","source":"Stock Titan","summary":"Enzon (ENZN) completes 1-for-100 reverse split; OTCQB trading as ENZND - Stock Titan","headline":"Enzon (ENZN) completes 1-for-100 reverse split; OTCQB trading as ENZND","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOUFN5N0RvdWl5SlhmVG01Z2Q3RG1sbUUySU1nWXZ0TVZiSUxRYjIzSGJxSE1BTzZPUUNnTWliTXh2UnZlWmhBT2hvMmRjQmtaV0NEZ3R2MkVXbkhmSTdoSWlJd0V1Rk9xVThXU3VmaG9MNW5XUXdxZElPQmsyOTVpSW4tYlh6eG9lRTV0eQ?oc=5","date":"2026-03-24","type":"deal","source":"Stock Titan","summary":"Enzon shrinks 100 shares into 1 as merger-related split begins - Stock Titan","headline":"Enzon shrinks 100 shares into 1 as merger-related split begins","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNSC1OUGRjTzlFb1RCemNMek9GNXZaYV90bnU5R3hibzZaSl8zcTk1bzVpOUZIdG5UdDlJRjdBYzQza3BoajBHYXRGakd5SFl6V05fN2xsQUJMV3lGbEdGUWVRRXhsS3I0YmtqU1FPTzlOOE5WR2VET3hmRTd1eGdNbUhtTU5UZHhaXzdqWlpUZUN3ZEp6b2RIb19fYm1lM3NIYUFOdkZGVExWWjVkNjJfSkNidnlHRVVfOFlTVnlCamhOcW1N?oc=5","date":"2026-03-19","type":"pipeline","source":"Stock Titan","summary":"Enzon (ENZN) extends Series C preferred exchange offer to March 24, 2026 - Stock Titan","headline":"Enzon (ENZN) extends Series C preferred exchange offer to March 24, 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxOWlpMeXgwOGgxVmVyOEpWdXFBNlhIX0F1R3JqaXJaaGtObVlLTFYtRU8wSHFJU0k5d25BWTd0a3JNTlM3U0FxcGFjeEplMUdMLVo1U2V2emFGM3ZSZE9zMUtTTkF4WDFZY1NsNjhTY3M0dThoWDZsZ1lkSEd1UTJmRFlvWWdZUDNaa1J5TS15N3QtdmRfb2FXUnhoYmZ0LTVVUldfWE82RFBtY3RKcElmSmJMVE14cXM5by1VYlU1eHJ6Q1kwYlNkeXlFOA?oc=5","date":"2026-01-30","type":"regulatory","source":"Stock Titan","summary":"Icahn group approves Enzon (ENZN) merger using 48.6% ownership stake - Stock Titan","headline":"Icahn group approves Enzon (ENZN) merger using 48.6% ownership stake","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOQWUzTTdxVENoZHdFSS14QXc1LWVXTG1vYmRvcTQ5UEdwa3ItZHBjNk5NMDVzbjEzbjJoWU1TOXlGcE1IZG5kR3htSWw5Smd2c1ZpVzJUaXpuaGt3RlRhazhDUGdtSHZlRjYycnFaQWktbUhfSUx0MmxjXzBtSno1b1Z6a25ZRDctMlJPZHl6ZzltcF9WWWJwN1pyUklJZm03eVF0R2ZfVmlFQjh0RHd0QUQxQmtvdHZa?oc=5","date":"2025-06-20","type":"deal","source":"globenewswire.com","summary":"Enzon and Viskase Enter into Merger Agreement - globenewswire.com","headline":"Enzon and Viskase Enter into Merger Agreement","sentiment":"neutral"}],"patents":[{"drugName":"Alkindi","drugSlug":"hydrocortisone","patentNumber":"","type":"Patent Cliff","expiryDate":"2033-06-01","territory":"US","annualRevenue":13400000},{"drugName":"Zinforo","drugSlug":"ceftaroline-fosamil","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":100000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":["Merck KGaA","Pfizer","Gilead Sciences"],"therapeuticFocus":["Endocrinology","Infectious Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":26000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":26000,"period":"2024-12-31"},{"value":26000,"period":"2024-12-31"},{"value":26000,"period":"2022-12-31"},{"value":26000,"period":"2022-12-31"},{"value":701000,"period":"2021-12-31"}],"grossProfit":36755000,"grossProfitHistory":[{"period":"2025-12-31","value":36755000},{"period":"2024-12-31","value":67830000},{"period":"2023-12-31","value":93763000}],"rdSpend":0,"rdSpendHistory":[],"sgaSpend":52471000,"operatingIncome":-17268000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-17268000},{"period":"2024-12-31","value":17800000},{"period":"2023-12-31","value":39721000}],"netIncome":-3409000,"netIncomeHistory":[{"period":"2025-12-31","value":-65494000},{"period":"2024-12-31","value":-5360000},{"period":"2023-12-31","value":13506000}],"eps":-1.017957,"epsHistory":[{"period":"2024-12-31","value":-1.017957},{"period":"2023-12-31","value":2.646688}],"cash":9217000,"cashHistory":[{"period":"2025-12-31","value":9217000}],"totalAssets":42813000,"totalLiabilities":257782000,"totalDebt":164004000,"equity":145843000,"operatingCashflow":12998000,"operatingCashflowHistory":[{"period":"2025-12-31","value":12998000},{"period":"2024-12-31","value":3369000},{"period":"2023-12-31","value":44165000}],"capex":-35363000,"capexHistory":[{"period":"2025-12-31","value":-35363000},{"period":"2024-12-31","value":-15279000},{"period":"2023-12-31","value":-14470000}],"freeCashflow":-22365000,"dividendsPaid":null,"buybacks":null,"employees":0,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":5.75,"previousClose":6.25,"fiftyTwoWeekHigh":8.55,"fiftyTwoWeekLow":0.02,"fiftyTwoWeekRange":"0.02 - 8.55","fiftyDayAverage":4.36,"twoHundredDayAverage":1.14,"beta":0,"enterpriseValue":207809728,"forwardPE":0,"priceToBook":-1.69,"priceToSales":0.11,"enterpriseToRevenue":0.58,"enterpriseToEbitda":-38.14,"pegRatio":0,"ebitda":-5449000,"ebitdaMargin":-1.5,"freeCashflow":-7767000,"operatingCashflow":-3446000,"totalDebt":151955008,"debtToEquity":79.7,"currentRatio":2.01,"returnOnAssets":-3.4,"returnOnEquity":-32.3,"analystRating":"","recommendationKey":"none","numberOfAnalysts":0,"targetMeanPrice":0,"targetHighPrice":0,"targetLowPrice":0,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.7,"institutionHeldPercent":93.7,"sharesOutstanding":6612125,"floatShares":0,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":-9.98,"epsForward":0,"revenuePerShare":2.64,"bookValue":-3.4,"officers":[{"age":73,"name":"Mr. Maurice J. Ryan","title":"Senior Vice President of Worldwide Sales"},{"age":56,"name":"Mr. Michael  Blecic","title":"Chief Accounting Officer & Treasurer"}],"industry":"Packaging & Containers","irWebsite":"","website":"https://www.viskase.com","phone":"(630) 874-0700"}}